Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active substance Guselkumab (exclusively in the strength 100mg), (OBO), ATC L04AC16 for the period 01.12.2024 - 30.11.2026
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Guselkumab (ausschließlich in der Wirkstärke 100mg), (OBO), ATC L04AC16 für die Zeit 01.12.2024 - 30.11.2026
Germany · Hamburg · how to bid here →
Your path to submission
- Deadline: 5 October at 12:00 — 1 day left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- The median procedure drew 9 bids (3,267 procedures with a bid count); 7% ended with a single bidder. Sector: median 2 bids.n = 3,267
- In this sector the buyer awards roughly every month (2862 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Sanofi-Aventis Deutschland GmbH.n = 2,862
- 81% of this buyer's awards went to companies that had already won here before (3,321 awards since 2017, spread over 567 companies). That is well above the sector norm (62%) — newcomers have a harder time here than elsewhere.n = 3,321 awards since 2017
- 83% of the bids received came from small and medium-sized enterprises (15 procedures with a bid mix). Sector: 38%.n = 15
- The award came in at a median 79% of the estimated value (6 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 6
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 01/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,111 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 11 (from 4,142 awards).
What the buyer is looking for
DAK-Gesundheit assumes that this procedure does not fall within the scope of antitrust law due to a lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. Irrespective of this, it ends automatically with the entry into force of the exclusive contract for guselkumab (only in the potency 100mg),ATC L04AC16, as a result of a formal procurement procedure under the regulations of Part 4 of the GWB with one or more contractual partners. In order to meet the diversity of potential contractual partners under the authorisation model, each pharmaceutical company will be able to conclude a framework contract at any time and under the same conditions during the contract period. The necessary contractual documents are available for download via the online portal www.dtvp.de/center under the link mentioned under 5.1.11. Prerequisites for the…
Show full description
… conclusion or later accession to the contracts, which will enter into force for the first time on 01.12.2024, are the complete and timely transmission of the following documents (available for download under the link mentioned under 5.1.11.) to the following department at DAK-Gesundheit: 1. Letter of Offer 2. Recognition of the contractual requirements of DAK-Gesundheit, in particular also of the predetermined discounts by submitting the contract with name or company stamp by the interested party at the designated place. 3. Completed Annexes 1 and 2 to the contract. The interested party must enter here the medicinal products for the above-mentioned active substance, which are to be the subject of the contract. The documents must be submitted by e-mail to: [email protected] DAK Health Department Pharmaceuticals (0038 00) Nagelsweg 27-31 20097 Hamburg Annex 2 is expressly to be sent as an Excel file to the e-mail address [email protected]. Contracts under this model and the above-mentioned active substance will be concluded for the first time with effect from 01.12.2024 and will end on 30.11.2026. Interested parties who wish to become contractual partners on this date must submit the above-mentioned documents by e-mail by the 5th of the previous month. The offer must be submitted in text form as an electronic offer PER E-MAIL to [email protected]. This procedure does not provide for the submission of tenders by post. Please DO NOT submit your tender via the German Public Procurement Portal. An electronic receipt of the complete documents PER E-MAIL to the e-mail address [email protected] is sufficient for the deadline to be met. Later accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the above-mentioned documents must be available to DAK Health by the 5th of the previous month, irrespective of the desired accession. Here, too, timely access by e-mail to the DAK-G is essential. Example: The accession requested by the tenderer is scheduled to take place on 15 July. (following month), the documents would have to be submitted by 05.06. (Previous month). Note: Publication is made here using the open procedure form. As already made clear, this is not one - the notice had to be used for technical reasons, as there is no form suitable for approval procedures.
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 184 | 2022–2026 |
| kohlpharma GmbH · Merzig | 168 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 134 | 2022–2026 |
| CC Pharma GmbH · Densborn | 131 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 121 | 2015–2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.